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1. INTRODUCTION 
                  As very few drugs are coming out of research and development and already 
existing drugs are suffering the problem of resistance due to their irrational use and 
complications involved in marketing new drug entities have increased, and moreover the 
desire to maintain a near-constant or uniform blood drug levels, as well as enhanced 
clinical efficacy of the drug for its intended use made some drugs more effective by slight 
alteration in the drug delivery. With concomitant recognition of the therapeutic 
advantages of Sustained drug delivery and Controlled drug delivery, greater attention has 
been focused on development of Sustained release drug delivery systems and Controlled 
drug delivery systems.  
Controlled Release Drug Delivery systems are the dosage forms designed to 
deliver the drug at a predetermined rate, locally or systemically, for a specified period of 
time. 
Sustained Release Drug Delivery systems are those that provide medication over 
an extended period of time. 
 
             
Figure :1 Comparative blood level profiles obtained from administration of 
conventional, controlled, and sustained release dosage forms.  
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The conventional tablet or capsule provides only a single and transient burst of 
drug. A pharmacological effect is seen as long as the amount of drug is within the 
therapeutic range. Problems occur when the peak concentration is above or below this 
range, especially for drugs with narrow therapeutic windows. The slow first order release 
obtained by a sustained release preparation is generally achieved by slowing the release 
of drug from a dosage form. In some cases this is accomplished by a continuous release 
process however systems that release small bursts of drug over a prolonged period can 
mimic the continuous release system.   
1.1  Drawbacks of Conventional Dosage Forms 
 Drugs with short half-life require frequent administration, which increases 
chances of missing dose of drug leading to poor patient compliance. 
 A typical peak-valley plasma concentration-time profile is obtained which makes 
difficult to attainment of steady state condition.  
 The unavoidable fluctuations in the drug concentration may lead to under 
medication or overmedication as the CSS values fall or rise beyond the therapeutic 
range.  
 The fluctuating drug levels may lead to precipitation of adverse effects especially 
of a drug with small therapeutic index, whenever overmedication occurs.  
In order to overcome the drawbacks of conventional drug delivery systems, several 
technical advancements have led to the development of controlled and sustained drug 
delivery system. However despite of many advantages offered by oral sustained release 
dosage forms they have few disadvantages and Lag time is one of them. Sustained 
Release also provides promising way to decrease the side effects of the drug by 
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preventing the fluctuation of the therapeutic concentration of the drug in the body. There 
are several reasons for the attractiveness of these dosage forms (Ansel et al., 2003). 
1.2 Sustained Release Drug Delivery Systems: 
Sustained release drug delivery systems can be defined as any dosage form that 
prolongs the therapeutic activity of the drug by continuously releasing medication over an 
extended period of time. In absence of suitable clinical evidence of this therapeutic effect 
it can be defined as any dosage forms that give prolongation of the drug levels in the 
blood. The major advantage of this category is that, in addition to the convenience of 
reduced frequency administration, it provides levels that are devoid of the peak and valley 
effect (Altaf et al., 2003). 
By providing smooth plasma level of drug over longer period of time, sustained -
release drug delivery technology can minimize side effects, improve efficacy and by 
enabling once daily dosing- maximize patient compliance.  
1.2.1 The goal in designing Sustained release delivery system is to:  
 Reduce the frequency of dosing or to increase effectiveness of the drug by 
localization at the site of action, reducing the dose required, or providing uniform 
drug delivery.  
 It would be a single dose for the duration of treatment whether it is for days or 
weeks, as with infection, or for the life time of the patient, as in hypertension or 
diabetes.  
 It should deliver the active entity directly to the site of action, minimizing or 
eliminating side effects.  
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 This may necessitate delivery to specific receptors or to localization to cells or to 
specific areas of the body.  
 The safety margin of high potency drug can be increase and the incidence of both 
local and systemic adverse side effects can be reduced in sensitive patient.  
Introduction of matrix tablet as sustained release (SR) has given a new 
breakthrough for novel drug delivery system (NDDS) in the field of Pharmaceutical 
technology. It excludes complex production procedures such as coating and pelletization 
during manufacturing and drug release rate from the dosage form is controlled mainly by 
the type and proportion of polymer used in the preparations. Hydrophilic polymer matrix 
is widely used for formulating an SR dosage form. Matrix system is widely used for the 
purpose of sustained release. It is the release system which prolongs and controls the 
release of the drug that is dissolved or dispersed. In fact, a matrix is defined as a well-
mixed composite of one or more drugs with gelling agent i.e. hydrophilic polymers. By 
the sustained release method therapeutically effective concentration can be achieved in 
the systemic circulation over an extended period of time, thus achieving better 
compliance of patients. Numerous SR oral dosage forms such as membrane controlled 
system, matrices with water soluble/insoluble polymers or waxes and osmotic systems 
have been developed, intense research has recently focused on the designation of SR 
systems for poorly water soluble drugs.  
Various drug delivery techniques have been developed to sustain the release of 
drugs, including triple-layered tablets (Geomatrix® technology) and osmotic pumps with 
laser drilled holes (OROS® technology). These technologies are intricate and relatively 
expensive to manufacture. Thus, there remains an interest in developing novel 
formulations that allow for sustained release of drugs using readily available, inexpensive 
excipients. 
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                Sustained Release systems generally don’t attain zero order type release and 
usually try to mimic zero order release by providing drug in a slow first order. Repeat 
action tablet are an alternative method of sustained release in which multiple doses of 
drug are an alternative method of sustained release, in which, multiple doses are 
contained within a dosage form and each dose is released at a periodic interval. Delayed 
release system, in contrast, may not be sustaining, since often the function of these dosage 
forms is to maintain the drug in the dosage for some time before release, for example; 
Enteric coated tablet. 
                The ideal way of providing an exact amount of drug at the site of action for a 
precise time period is usually approximated by most systems. This approximation is 
achieved by creating a constant concentration in the body or an organ over an extended 
time; in other words, the amount of drug entering the system is equivalent to the amount 
of drug removed from the system. All forms of metabolism and excretion are included in 
the removal process; urinary excretion, enterohepatic recycling, sweat, fecal and so on. 
Since, for most of the drugs these elimination processes are first order, it can be said that 
a certain blood level, the drug will have a specific rate of elimination. The idea is to 
deliver drug at this exact rate for an extended period. This is represented mathematically 
as following,           
                                         Rate in = Rate out = kelim × Cd × Vd 
Where Cd is the desired drug level, Vd is the volume of distribution, and k elim is 
the rate constant of drug elimination from the body. Often such exacting delivery rates 
prove to be difficult to achieve by administration routes other than intravenous infusion. 
Non-invasive routes, for example. Oral are obviously preferred. 
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1.2.2 Designing Sustained Release Drug Delivery Systems: 
  Most of the orally administered drugs, targeting is not a primary concern and it is 
usually intended for drugs to penetrate to the general circulation and perfuse to other body 
tissues. For this reason, most systems employed are of the sustained release variety. 
Sustained release dosage forms usually consists of two parts; an immediately available 
dose to establish blood level quickly and a sustained part that contains several times the 
therapeutic dose for predicted drug levels (Robinson JR et al., 2005). 
 Several are available to add the immediately available portion to the sustaining part. 
Simple addition of non-sustained portion to the tablet is the most direct method. 
Placement of initial dose in the tablet coat with the sustaining portion in the core 
represents an alternate approach. More common methods that are used to achieve 
sustained release of orally administered drugs are as follows:  
1. Dissolution Controlled Systems  
 Encapsulation dissolution control 
 Matrix Dissolution control 
2. Diffusion Controlled Systems 
 Reservoir devices 
 Matrix devices 
3. Diffusion and Dissolution Controlled Systems 
4. Ion exchange resins 
5. pH independent formulations 
 It is assumed that increasing concentration at the absorption site will increase 
circulating blood levels, which in turn, promotes greater concentration of drug at the site 
of action. If toxicity is not an issue, therapeutic levels can thus be extended. In essence, 
drug delivery by these systems usually depends on release from some type of dosage 
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form, permeation through biological milieu and absorption through an epithelial 
membrane to the blood.  
There are a variety of both physicochemical and biological factors that come into 
play in the design of such system. 
Biological factors influencing oral sustained-release dosage form design: 
 Biological half life. 
 Absorption. 
 Metabolism. 
 Side effects 
 
Biological half life: 
                 The usual goal of an oral SR product is to maintain therapeutic blood levels 
over an extended period of time. To achieve this, drug must enter the circulation at 
approximately the same rate at which it is eliminated. The elimination rate is 
quantitatively described by the half-life (t1/2). Each drug has its own characteristic 
elimination rate, which is the sum of all elimination processes, including metabolism, 
urinary excretion and all over processes that permanently remove drug from the blood 
stream. Therapeutic compounds with short half-life are generally are excellent candidate 
for SR formulation, as this can reduce dosing frequency. In general, drugs with halflives 
shorter than 2 hours such as furosemide or levodopa are poor candidates for SR 
preparation. Compounds with long half-lives, more than 8 hours are also generally not 
used in sustaining form, since their effect is already sustained. Digoxin and phenytoin are 
the examples. 
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Absorption: 
                  Since the purpose of forming a SR product is to place control on the delivery 
system, it is necessary that the rate of release is much slower than the rate of absorption. 
If we assume that the transit time of most drugs in the absorptive areas of the GI tract is 
about 8-12 hours, the maximum half-life for absorption should be approximately 3-4 
hours; otherwise, the device will pass out of the potential absorptive regions before drug 
release is complete. Thus corresponds to a minimum apparent absorption rate constant of 
0.17-0.23h-1 to give 80-95% over this time period. Hence, it assumes that the absorption 
of the drug should occur at a relatively uniform rate over the entire length of small 
intestine. For many compounds this is not true. 
               If a drug is absorbed by active transport or transport is limited to a specific 
region of intestine, SR preparation may be disadvantageous to absorption. One method to 
provide sustaining mechanisms of delivery for compounds tries to maintain them within 
the stomach. This allows slow release of the drug, which then travels to the absorptive 
site. These methods have been developed as a consequence of the observation that co-
administration results in sustaining effect. One such attempt is to formulate low density 
pellet or capsule. Another approach is that of bioadhesive materials. 
Metabolism: 
              Drugs those are significantly metabolized before absorption, either in the lumen 
or the tissue of the intestine, can show decreased bioavailability from slower-releasing 
dosage form. Hence criteria for the drug to be used for formulating Sustained-Release 
dosage form is, 
 Drug should have low half-life(<5 hrs) 
 Drug should be freely soluble in water. 
 Drug should have larger therapeutic window. 
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 Drug should be absorbed throughout the GIT. 
 
Even a drug that is poorly water soluble can be formulated in SR dosage form. For the 
same, the solubility of the drug should be increased by the suitable system and later on 
that is formulated in the SR dosage form. But during this the crystallization of the drug, 
that is taking place as the drug is entering in the systemic circulation, should be prevented 
and one should be cautious for the prevention of the same. 
Side Effects: 
              It is believed that for some drugs, the incidence of side effects is a function of 
plasma concentrations. Theoretically, the incidence of side effects can be minimized by 
controlling the concentration at which the drug exists in plasma at any given time, and 
hence controlled release formulations appear to offer a solution to this problem.  
Some other factors that influence include Duration of action, Margin of Safety, 
Role of Disease state and Role of Circadian Rhythm. 
 
Physicochemical factors influencing oral sustained-release dosage form design 
Dose size: 
             For orally administered systems, there is an upper limit to the bulk size of the 
dose to be administered. In general, a single dose of 0.5-1.0g is considered maximal for a 
conventional dosage form. This also holds for sustained release dosage form. Compounds 
that require large dosing size can sometimes be given in multiple amounts or formulated 
into liquid systems. Another consideration is the margin of safety involved in 
administration of large amount of a drug with a narrow therapeutic range. 
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Ionization, pka and aqueous solubility: 
                 Most drugs are weak acids or bases. Since the unchanged form of a drug 
preferentially permeates across lipid membranes, it is important to note the relationship 
between the pka of the compound and the absorptive environment. Presenting the drug in 
an unchanged form is advantageous for drug permeation. Unfortunately, the situation is 
made more complex by the fact that the drug’s aqueous solubility will generally be 
decreased by conversion to unchanged form. Delivery systems that are dependent on 
diffusion or dissolution will likewise be dependent on the solubility of the drug in 
aqueous media. 
                These dosage forms must function in an environment of changing pH, the 
stomach being acidic and the small intestine more neutral, the effect of pH on the release 
process must be defined. Compounds with very low solubility (<0.01mg/ml) are 
inherently sustained, since their release over the time course of a dosage form in the GI 
tract will be limited by dissolution of the drug. So it is obvious that the solubility of the 
compound will be poor choices for slightly soluble drugs, since the driving force for 
diffusion, which is the drug’s concentration in solution, will be low. 
Partition Coefficient 
                  When a drug is administered to the GI tract, it must cross a variety of 
biological membranes to produce a therapeutic effect in another area of the body. It is 
common to consider that these membranes are lipidic; therefore the partition coefficient 
of oil-soluble drugs becomes important in determining the effectiveness of membrane 
barrier penetration. 
               Compounds which are lipophilic in nature having high partition coefficient are 
poorly aqueous soluble and it retain in the lipophilic tissue for the longer time. In case of 
compounds with very low partition coefficient, it is very difficult for them to penetrate 
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the membrane, resulting in poor bioavailability. Furthermore, partitioning effects apply 
equally to diffusion through polymer membranes. The choice of diffusion-limiting 
membranes must largely depend on the partitioning characteristics of the drug. 
Stability 
             Orally administered drugs can be subject to both acid-base hydrolysis and 
enzymatic degradation. Degradation will proceed at a reduced rate for drugs in solid state; 
therefore, this is the preferred composition of delivery for problem cases. For the dosage 
form that are unstable in stomach, systems that prolong delivery over entire course of 
transit in the GI tract are beneficial; this is also true for systems that delay release until 
the dosage form reaches the small intestine. Compounds that are unstable in small 
intestine may demonstrate decreased bioavailability when administered from a sustaining 
dosage form. This is because more drugs is delivered in the small intestine and, hence, is 
subject to degradation. Propentheline and Probanthine are representative example of such 
drug. 
1.2.3 Advantages of Sustained Release Drug Delivery Systems:  
Sustained release products offer many potential benefits over the conventional 
dosage formulations. They are; 
 Sustained blood levels 
 For drugs with relatively short half lives, the use of sustained-release products 
may maintain therapeutic concentrations over prolonged periods.  
 Dosage frequency reduction 
 Minimize or eliminate local side effects. 
 Minimize or eliminate systemic side effects.  
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 Obtain less potentiation or reduction in drug activity with chronic use. 
 Minimize drug accumulation with chronic dosing.  
 Improved patient compliance 
 A reduction in the number of daily doses offered by sustained release products has 
the potential to improve compliance. 
Improve efficiency in treatment 
 Reduced peak to trough ratio of drug in systemic circulation. 
 Improves control of condition i.e., reduced fluctuation in drug level. 
 Improves bioavailability of some drugs. 
 Reduced rate of rise of drug concentration in blood.  
 Sustained & Consistent blood level with in the therapeutic window. 
 Customized delivery profiles eg. Sustained release aspirin for morning relief of 
arthritis by dosing before bedtime.  
Economy i.e. reduction in health care costs.  
 The average cost of treatment over an extended time period may be less, with less 
frequency of dosing, enhanced therapeutic benefits and reduced side effects.  
 The time required for health care personnel to dispense and administer the drug 
and monitor patient is also reduced.  
Disadvantages 
 Sustained release products contain a higher drug load and thus any loss of 
integrity of the release characteristics of the dosage form has potential problems.  
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 The larger size of sustained release products may cause difficulties in ingestion or 
transit through the gut.  
 Sustained release products may cause decreased systemic availability in 
comparison to conventional dosage forms, which may be due to incomplete 
release, increased first-pass metabolism, increased instability, insufficient 
residence time for complete release, site specific absorption, pH dependent 
stability etc.  
 Possibility of dose dumping due to food, physiologic or formulation variables or 
chewing or grinding of oral formulations by the patient and thus, increased risk of 
toxicity.        
1.2  Bilayered Tablets:s 
In order to achieve sustained therapeutic action oral SRDDS will release the drug 
at a slow rate and thus during the initial stages of medication, the plasma drug 
concentration generally stays below the minimum effective concentration and as a result 
the patient does not get any therapeutic benefit. 
Bilayered SR tablets are a solution to above problem. These preparations provide 
an immediate dose required for the normal therapeutic response, followed by the gradual 
release of drug in amounts sufficient to maintain the therapeutic response for a specific 
period of time. The major advantage of this category is that, in addition to the 
convenience of reduced frequency administration, it provides levels that are devoid of the 
peak and valley effect. 
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 They contain two layers formulated with the same drug or two different drugs. 
The first layer is a fast releasing layer consisting a loading dose of the drug while the 
second layer is a sustaining layer containing maintenance dose of the drug. 
 
 
 
 
 
 
Fig 2:Drug release from Bilayered tablet: 
                    
 Loading dose layer: provides initial burst release that takes the drug concentration 
above MEC. 
 Maintenance dose layer: provides slow sustained release that maintains the drug 
concentration above the MEC for the remaining period.                                                                                                                                                                           
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2. REVIEW OF LITERATURE 
2.1 Past Studies on Bilayered tablets 
    Chitra karthikeyini.S et.al., formulated Bilayered tablets of Aceclofenac sodium. 
The Immediate release layer of bilayer tablet of aceclofenac sodium comprised of  super 
disintegrant sodium starch glycolate for fast release layer and Eudragit RL 100 for 
sustaining layer. Bilayer tablets showed an initial burst effect to provide the loading dose 
of drug, followed by sustained release for 24 hrs. This modified release bilayer tablets 
also reduced dosing frequency, increase the bioavailability and provide better patient 
compliance. 
    Chowdary. K. P. R et.al., formulated Bilayered tablets of 10mg Glipizide by Wet 
granulation method with an immediate release layer consisted of Ac-Di-Sol and the 
sustained release layer consisted of Na CMC or HPMC with 5% ethyl cellulose as 
polymers. Both the bilayered tablets designed with Na CMC or HPMC with 5% ethyl 
cellulose gave glipizide release close to the theoretical Sustained Release needed for 
glipizide i.e; the polymers used sustained the release of the drug for a prolonged period of 
time.  
    Deelip derle et.al., has formulated and evaluated mucoadhesive bi-layer buccal 
tablets of propranolol hydrochloride tablets using the bioadhesive polymers such as 
sodium alginate and carbopol 971 P along with ethyl cellulose as an impermeable backing 
layer. The tablets were evaluated for weight variation, thickness, hardness, friability, 
surface pH, mucoadhesive strength, swelling index, in vitro drug release. Tablets 
containing sodium alginate and carbopol 971 P in the ratio of 5:1 showed the maximum 
percentage of in vitro drug release without disintegration in 12 hours. The swelling index 
was proportional to sodium alginate content and inversely proportional to carbopol 971 P 
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content. The surface pH of all tablets was found to be satisfactory, close to neutral pH; 
hence, no irritation would observe with these tablets. The mechanism of drug release was 
found to be zero-order kinetics. 
    Doddayya Hiremath et.al., formulated Bilayered tablets of Losartan Potassium by 
Direct Compression technique employing HPMC, xanthan gum and gum karaya as a 
polymers. The immediate release layer was formulated employing Sodium Starch 
Glycolate as the super disintegrant. Bilayer tablets showed an initial burst to provide the 
loadingdose of the drug, followed by the sustained release, indicating a promising 
potential of the losartan potassium bilayer tablet as an alternative to the conventional 
dosage form. 
    K.Shivanand et.al., Investigated on mucoadhesive bilayered buccal tablets of 
Tizanidine Hydrochloride (TZD HCl), using mucoadhesive polymers Carbopol 934(CP), 
HPMC K4M, HPMC K15M and Sodium carboxymethylcellulose along with ethyl 
cellulose as an impermeable backing layer. Preformulation studies of TZD HCl like 
compatibility studies with polymers, using FTIR and DSC were carried out. The bilayered 
buccal tablets were evaluated for weight variation, thickness, hardness, friability, surface 
pH, mucoadhesive strength, mucoadhesive time, swelling index, in vitro drug release and 
ex vivo permeation. FTIR and DSC found to be compatible with selected polymers. 
Bilayered buccal tablets containing CP and HPMC K4M in the ratio 1:1 (BT1) had the 
maximum percentage of in vitro drug release in 6 hours. The swelling index of the tablets 
increased with increasing amounts of CP. The optimized formulation (BT1) follows non-
Fickian release mechanism. 
    Nagaraju. R  et.al., formulated Sustained Release Bilayered tablets of Salbutamol 
and Theohylline by wet granulation method in which Immediate release granules 
                                                                                                                   Literature Review 
 
J.K.K.Nattraja College of Pharmacy 17 
 
 
containing Salbutamol alone and the Sustained release layer consisting of both 
Salbutamol and Theophylline. The IR layer comprise of HPMCK4M, PVPK30 and starch 
whereas the SR layer comprise of various polymers, such as hydroxy propyl 
methylcellulose K4M (HPMC- K4M), hydroxy propyl methylcellulose K100M (HPMC- 
K100M), xanthan gum, ethyl cellulose and hydroxy propyl methylcellulose phthalate 
(HPMC-P) were studied. 
    Nakhat et.al., developed buccoadhesive bilayered tablets of terbutaline sulphate were 
prepared by direct compression method using bioadhesive polymers like Carbopol 934P, 
Methocel K4M, Methocel K15M and sodium carboxy methyl cellulose either alone or in 
combinations with backing layer of ethyl cellulose. The physical characteristics, swelling 
index, surface pH, in vitro bioadhesion strength, and in vitro release of formulated tablets 
were shown to be dependent on characteristics and composition of bioadhesive materials 
used. The modified in vitro assembly was used to measure and compare the bioadhesive 
strength of tablets with fresh porcine buccal mucosa as a model tissue. The maximum 
bioadhesive strength was observed in tablets formulated with Carbopol 934P alone and 
strength decreases with decrease in its content. All the formulations followed non-Fickian 
release mechanism. Carbopol 934P and Methocel K4M in the ratio of 1:1 could be used 
to design effective and stable buccoadhesive tablets of terbutaline sulphate.  
    Patra. C.N et.al., developed a bilayered tablet of propranolol hydrochloride using 
superdisintegrant sodium starch glycolate for the fast release layer and water immiscible 
polymers such as ethylcellulose, Eudragit RLPO and Eudragit RSPO for the sustaining 
layer. They concluded that the bilayered tablets showed an initial burst effect to provide 
the loading dose of the drug, followed by sustained release for 12 h, indicating a 
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promising potential of the propranolol hydrochloride bilayered tablet as an alternative to 
the conventional dosage form. 
    Prasanthi NL et.al., formulated Bilayered tablets of Propronolol Hydrochloride by 
wet granulation method. The Immediate release layer was formulated using sodium starch 
glycolate as the super disintegrant. The sustained release layer comprised of Xanthan 
gum, Locust bean gum and Guar gum as the polymers. From all the formulations over 
35% of propanolol was released within the first hour of dissolution study. It was observed 
that bi‐layered tablets prepared with xanthan gum were retarding the drug release more 
when compared with the tablets prepared with locust bean gum, guar gum. 
    Raghavendra Rao. N.G et.al., formulated Bilayered tablets of 5mg Glipizide by Wet 
granulation method using 1:2 ratio of Glipizide and Mannitol solid dispersion in the 
immediate release layer. Sustained release layer was designed by the use of synthetic 
matrix materials like various grades of HPMC, ethyl cellulose and the natural matrix 
forming materials like Xanthan gum, Guar gum, Gum Karaya. Finally they concluded 
that the ideal zero order release pattern was achieved by the blend of HPMC K100M, 
HPMC K15M and Ethyl cellulose, xanthan gum, guar gum, karaya gum can be used as 
rate controlling polymers by appropriate selection of the level of polymers in the matrix 
tablets. 
    Ramesh et.al., formulated Bilayered tablets of Metformin hydrochloride and 
Pioglitazone.  Immediate release  Pioglitazone layer was formulated by Dry granulation 
and Sustained release Metformin Hydrochloride was formulated by Wet granulation. 
Immediate release layer comprised of Cross caramellose sodium as super disintegrant and 
the Sustained release layer comprised of HPMCK4M, HPMC 15cps, and Na CMC as 
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polymers. Bilayered tablet showed an immediate release effect to provide the loading 
dose of the drug, followed by sustained release for eight hrs.  
    Sonia Pandey et.al., has developed buccoadhesive bilayered tablets of carvedilol 
were prepared by direct compression method using bioadhesive polymers like carbopol 
934P and HPMC K4M.The formulations were tested for in vitro drug release, in vitro 
bioadhesion, moisture absorption and in vitro drug permeation through porcine buccal 
mucosa. The dissolution of Carvedilol from all the prepared tablets into phosphate buffer 
(pH 6.8) was controlled and followed by non-fickian release mechanism. Dissolution 
studies of the tablets of optimized batch containing 5% Carbopol 934P/65% HPMC 
K4M/30% lactose showed 82.7 % release of drug in 6 h. The mucoadhesive strength and 
residence time of the optimized batch are 17.93 g and 9.45 h respectively. The swelling 
index and microenvironment pH of the optimized batch after 6 h are 77.54 and 6.76 
respectively. Procured sample of carvedilol was tested for its identification by taking 
FTIR of pure drug. Drug excipient compatibility was done at 30°C, 65% ± 5%RH and 
40°C 75% ± 5% RH using open and closed vial for four weeks and observed for physical 
changes. Result does not show any physical changes to mixture after 4 weeks. The results 
indicate that suitable bioadhesive bilayered buccal tablets with desired permeability using 
5-6% Carbopol 934P, 65-68%HPMC K4M and 30% Lactose. 
    Swamy P V et.al., has formulated and evaluated buccoadhesive Bilayer tablets of 
granisetron hydrochloride. Bilayer buccal tablets containing the drug were prepared by 
direct compression method using combination of polymers (such as hydroxypropyl 
methylcellulose 15 cps, sodium carboxymethyl cellulose and Carbopol 934p.) and ethyl 
cellulose as backing layer. The designed tablets were evaluated for various physical and 
biological parameters, drug content uniformity, in-vitro drug release, short-term stability, 
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drug- excipients interactions (FTIR).The formulation HF1 with the drug matrix layer 
composition- hydroxypropyl methylcellulose 15 cps (47% w/w), Carbopol 934p 
(3%w/w), and mannitol was found to be promising. This optimized formulation exhibited 
an in vitro drug release of 94% in 8 h along with satisfactory bioadhesion strength (4.3 
gm). Short-term stability studies on the promising formulation indicated that there are no 
significant changes in drug content and in vitro dissolution characteristics (p<0.05). IR 
spectroscopic studies indicated that there are no drug-excipient interactions.  The present 
study proves that buccoadhesive bilayer tablets of granisetron hydrochloride with 
controlled drug release properties can be successfully prepared by direct compression 
method using HPMC 15 cps and Carbopol 934p as mucoadhesive polymers and ethyl 
cellulose as backing layer. 
    Vijaya Kumar. B et.al.,    formulated Sustained release Bilayered tablets of 
Guaifenesin  by wet granulation. The immediate release granules consists of Sodium 
starch glycolate as the super disintegrant and concluded that 20% of drug was released 
within first 30 minutes. The sustain release granules were formulated using Metalose 90 
SH and Carbopol as polymers inorder to sustain the release. The bilayered tablets showed 
biphasic release, in the first phase the first fraction of the dose (immediate dose) was 
released as a burst effect because of fast releasing components of loading layer then 
second phase was released from matrix layer as a controlled non fickian diffusion release 
fashion. 
    Vinoth Kumar.G  et.al ., formulated Bilayered tablets of Cefixime trihydrate and 
Dicloxacillin sodium to avoid incompatibility. Bilayered tablets were formulated by wet 
granulation method in which one layer contains sustained release drug Dicloxacillin 
sodium and another layer contains immediate release drug Cefixime tri hydrate. 
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Dicloxacillin sodium layer was formulated using Povidone, HPMCK4M, HPMCK15M 
for sustained release and the immediate release layer of Cefixime trihydrate was 
formulated with Cross caramellose sodium. 
    Vishnu M. Patel et.al.,  has developed and characterized mucoadhesive bilayer 
buccal tablets of propranolol hydrochloride using the bioadhesive polymers sodium 
alginate (Na-alginate) and Carbopol 934P (CP) along with ethyl cellulose as an 
impermeable backing layer. The tablets were evaluated for weight variation, thickness, 
hardness, friability, surface pH, mucoadhesive strength, swelling index, in vitro drug 
release, ex vivo drug permeation, ex vivo mucoadhesion, and in vivo pharmacodynamics 
in rabbits. Tablets containing Na-alginate and CP in the ratio of 5:1 (F2) had the 
maximum percentage of in vitro drug release without disintegration in 12 hours. The 
swelling index was proportional to Na-alginate content and inversely proportional to CP 
content. The surface pH of all tablets was found to be satisfactory (7.0 ± 1.5), close to 
neutral pH; hence, buccal cavity irritation should not occur with these tablets. The 
mechanism of drug release was found to be non-Fickian diffusion and followed zero-
order kinetics. The formulation F4 was optimized based on good bioadhesive strength 
(28.9 ± 0.99 g) and sustained in vitro drug permeation (68.65% ± 3.69% for 12 hours). 
The behavior of formulation F4 was examined in human saliva, and both the drug and the 
buccal tablet were found to be stable. The formulation F4 was applied to rabbit oral 
mucosa for in vivo studies. The formulation inhibited isoprenaline-induced tachycardia. 
The studies conducted in rabbits confirmed the sustained release as compared with 
intravenous administration. 
2.2 Past Studies on Pioglitazone HCl: 
   Hallakou.S et.al., aimed at improving insulin sensitivity would promote the 
recruitment of new adipocytes in vivo. To address this problem, they have studied the 
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in vivo effect of pioglitazone on glucose metabolism and gene expression in the 
adipose tissue of an animal model of obesity with insulin resistance, the obese Zucker 
(fa/fa) rat. Pioglitazone markedly improves insulin action in the obese Zucker (fa/fa) 
rat, but doubles its weight gain after 4 weeks of treatment. 
    Hofmann et.al., studied the Glucose Transport Deficiency in Diabetic Animals by 
Treatment with the Oral Antihyperglycemic Agent Pioglitazone HCl. 
    Kemnitz J W et.al., The antidiabetic effects of pioglitazone hydrochloride were 
evaluated in 6 spontaneously obese, insulin-resistant rhesus monkeys. The animals were 
studied during six successive 2-wk treatment phases separated by 2-wk rest periods. 
    Mehmood A. Khan, MD, et.al., Studied the metabolic effects of pioglitazone or 
rosiglitazone in patients with type 2 diabetes who were previously treated with 
troglitazone. 
    Mozhgan Dorkhan, Anders Frid, studied the mechanism of action and clinical data 
behind the use of Pioglitazone HCl in management of type 2 diabetes in terms of 
glycemic and non-glycemic effects, tolerability and side effects, impact on vascular 
health. 
 2.3 Past Studies on Metformin HCl: 
    Kah Hay Yuen, Kok Khiang Peh and Boon Li Tan studied bioavailability of two 
controlled-release metformin preparations (Diabetmin Retard and Glucophage Retard) 
and also to correlate the in vitro and in vivo data obtained with the two preparations. 
    Meltem Cetin,  Alptug Atila, Selma Sahin, Imran Vural  developed the metformin 
HCl-loaded nanoparticle formulations. Nanoparticles were prepared by the 
nanoprecipitation method using both a single polymer (Eudragit®RSPO) and a polymer 
mixture (Eudragit/PLGA). The mean particle size ranged from 268.8 to 288 nm and the 
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nanoparticle surface was positively charged (9.72 to 10.1 mV). The highest encapsulation 
efficiency was observed when Eudragit®RSPO was used. All formulations showed 
highly reproducible drug release profiles and the in vitro drug release in phosphate buffer 
(pH = 6.8) ranged from 92 to 100% in 12 h. 
    Patil SA,  Kuchekar BS,  Chabukswar AR, and  Jagdale SC studied the 
formulation and characterization of solid dispersion (SD) of metformin hydrochloride 
using methocel K100M as the carrier by the solvent evaporation and cogrinding method. 
The influence of drug polymer ratio on drug release was studied by dissolution tests. 
    Subal Chandra Basak,Kesevan Senthil Kumar, Murugesan Ramalingam 
formulated Metformin hydrochloride as a hydrophobic matrix sustained release tablet 
employing wax materials and the sustained release behavior of the fabricated tablet was 
investigated. Sustained release matrix tablets containing 500 mg metformin HCl were 
developed using different bees wax combinations. The tablets were prepared by wet 
granulation technique. The formulation was optimized on the basis of acceptable tablet 
properties and in vitro drug release. 
2.4 Past Studies on Bilayered tablets of Pioglitazone HCl and Metformin HCl: 
    Aziz Karim et.al., studied the Bioavailability of pioglitazone and metformin, in 2 
dose strengths, given either as a fixed-dose combination tablet or as coadministration of 
commercial tablets (coad), was studied in young healthy subjects in 2 separate studies. In 
study I (n = 63), single oral doses of 15-mg pioglitazone/500-mg metformin fixed-dose 
combination tablets or equivalent doses of commercial tablets were administered, in a 
fasting state, in an open-label, randomized, crossover study with a 7-day washout period 
between treatments. Study II (n = 61) was similar in design to study I, except the 15/850-
mg fixed-dose combination tablet and coad treatments were evaluated. 
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3. AIM AND OBJECTIVES, PLAN OF WORK 
The aim of this investigation is to Design and Develop Bilayered oral sustained matrix 
tablets of Pioglitazone hydrochloride and Metformin hydrochloride. 
               The concept of Bilayered tablet technology is utilized for stabilization of two 
incompatible drugs, taste masking of drugs, delivering two drugs having synergistic 
effects or to deliver a drug for biphasic drug release profile and for the purpose of 
extension of patents. A Bilayered tablet comprises of two layers among which the first 
layer is immediate release layer for sudden onset of action and the second layer is 
Sustained release layer to maintain the steady state concentrations of drug in the blood. 
              Pioglitazone HCl is thiazolidinedione (TZD) class of drug with hypoglycemic, 
antihyperglycemic and antidiabetic action. Chemically Pioglitazone is (RS)-5-(4-[2-(5-
ethylpyridin-2-yl) ethoxy] benzyl) thiazolidine-2, 4-dione. Pioglitazone is used for the 
treatment of diabetes mellitus type 2 (previously known as non-insulin-dependent 
diabetes mellitus, NIDDM) in monotherapy and in combination with a sulfonylurea, 
Metformin. Pioglitazone has also been used to treat non-alcoholic fatty liver. Pioglitazone 
has also been found to reduce the risk of conversion from prediabetes to diabetes mellitus 
type 2 by 72%. It has short biological half life of 3-5 hrs (Ramesh et al).  
Metformin HCl is a biguanide oral anti hyperglycemic (anti diabetic) agent. It is 
used as an adjunct to diet and exercise for the management of type 2(non-insulin-
dependent diabetes mellitus) diabetes mellitus in patients whose hyperglycemia cannot be 
controlled by diet alone. As Metformin HCl possess short biological half life (1.5-4.5 
hrs), patient should go for frequent administration usually twice or thrice a day which 
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might be a risk to the patient. In order to overcome this Metformin HCl sustained release 
dosage forms are formulated (Ramesh et al). 
PLAN OF WORK: 
1. To formulate and evaluate the Bilayered tablets of Pioglitazone HCl and 
Metfofmin HCl. 
2. To carry out the drug - excepient compatibility studies by IR spectral analysis. 
3. To carry out the Precompressional parameters for the powder blend of IR layer of 
Bilayered tablets.  
4. To carry out the Precompressional and Postcompressional parameters for 
Bilayered tablets.  
5. To study the release kinetics and transport mechanism of drug from the formulations.  
6. To study the comparative release profiles of tablets formulated with marketed 
formulation using the similarity factor. 
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4. DRUG & EXIPIENTS PROFILE 
4.1 PIOGLITAZONE HCl 
              Pioglitazone HCl is thiazolidinedione (TZD) class of drug with hypoglycemic, 
antihyperglycemic and antidiabetic action. Pioglitazone is used for the treatment of 
diabetes mellitus type 2 (previously known as non-insulin-dependent diabetes mellitus, 
NIDDM) in monotherapy and in combination with a sulfonylurea, Metformin. 
Pioglitazone has also been used to treat non-alcoholic fatty liver. Pioglitazone has also 
been found to reduce the risk of conversion from prediabetes to diabetes mellitus type 2 
by 72%.  
Structure: 
                                  
 
Figure 3: Structure of   Pioglitazone HCl 
Molecular Formula:  C19H20N2O3S 
Molecular Weight    :  356.439 
Chemical Name        :  (RS)-5-(4-[2-(5-ethylpyridin-2-yl) ethoxy] benzyl) thiazolidine- 
                                       2, 4-dione. 
Description               :  whitish odourless powder  
Half-life                     :  3-5 hrs 
Melting Point            :  183-184oC 
pKa                            :  12.06 
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Mechanism of Action: 
Pioglitazone acts as an agonist at peroxisome proliferator activated receptors 
(PPAR) in target tissues for insulin action such as adipose tissue, skeletal muscle, and 
liver. Activation of PPAR-gamma receptors increases the transcription of insulin-
responsive genes involved in the control of glucose production, transport, and utilization. 
In this way, pioglitazone both enhances tissue sensitivity to insulin and reduces hepatic 
gluconeogenesis. Thus, insulin resistance associated with type 2 diabetes mellitus is 
improved without an increase in insulin secretion by pancreatic β cells. 
Pharmacodynamics: 
Pioglitazone, a member of the drug group known as the thiazolidinediones or 
"insulin sensitizers", is not chemically or functionally related to the alpha-glucosidase 
inhibitors, the biguanides, or the sulfonylureas. Pioglitazone targets insulin resistance and, 
hence, is used alone or in combination with insulin, metformin, or a sulfonylurea as an 
antidiabetic agent. 
Pharmacokinetics:  
Absorption: Following oral administration, in the fasting state, pioglitazone is first 
measurable in serum within 30 minutes, with peak concentrations observed within 2 
hours. Food slightly delays the time to peak serum concentration to 3 to 4 hours, but does 
not alter the extent of absorption. 
Distribution: The apparent volume of distribution at steady state was 0.63±0.41 
liters/kilogram. 
Metabolism: Metabolism Site is liver extensively. First pass metabolism is minimal.  
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Elimination: Following oral administration, approximately 15% to 30% of the 
pioglitazone dose is recovered in the urine. Renal elimination of pioglitazone is 
negligible, and the drug is excreted primarily as metabolites and their conjugates. It is 
presumed that most of the oral dose is excreted into the bile either unchanged or as 
metabolites and eliminated in the feces. 
Contraindications: Take without regard to meals. Food slightly delays absorption rate 
but extent of absorption is not affected. 
Dosage: initially 15 or 30 mg per day, maximum 45mg per day. 
 
4.2 METFORMIN HCl 
Metformin is a biguanide antihyperglycemic agent used for treating non-insulin-
dependent diabetes mellitus (NIDDM). It improves glycemic control by decreasing 
hepatic glucose production, decreasing glucose absorption and increasing insulin-
mediated glucose uptake. Metformin is the only oral antihyperglycemic agent that is not 
associated with weight gain. Metformin may induce weight loss and is the drug of choice 
for obese NIDDM patients. When used alone, metformin does not cause hypoglycemia; 
however, it may potentiate the hypoglycemic effects of sulfonylurea’s and insulin. Its 
main side effects are dyspepsia, nausea and diarrhea. Dose titration and/or use of smaller 
divided doses may decrease side effects. Metformin should be avoided in those with 
severely compromised renal function (creatinine clearance < 30 ml/min), 
acute/decompensated heart failure, severe liver disease and for 48 hours after the use of 
iodinated contrast dyes due to the risk of lactic acidosis. Lower doses should be used in 
the elderly and those with decreased renal function. Metformin decreases fasting plasma 
glucose, postprandial blood glucose and glycosolated hemoglobin (HbA1c) levels, which 
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are reflective of the last 8-10 weeks of glucose control. Metformin may also have a 
positive effect on lipid levels. 
Structure: 
                                  
Figure 4: Structure of   Metformin Hcl 
Molecular Formula:  C4H11N5 
Molecular Weight    :  129.164 
Chemical Name        :   1-carbamimidamido-N, N-dimethylmethanimidamide. 
Description               :  whitish odourless powder  
Half-life                     :   1.5-4.5 hrs 
Melting Point            :    223-226oC 
pKa                            :   12.4 
Mechanism of Action: 
           Metformin's mechanisms of action differ from other classes of oral 
antihyperglycemic agents. Metformin decreases blood glucose levels by decreasing 
hepatic glucose production, decreasing intestinal absorption of glucose, and improving 
insulin sensitivity by increasing peripheral glucose uptake and utilization. These effects 
are mediated by the initial activation by metformin of AMP-activated protein kinase 
(AMPK), a liver enzyme that plays an important role in insulin signaling, whole body 
energy balance, and the metabolism of glucose and fats. Activation of AMPK is required 
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for metformin's inhibitory effect on the production of glucose by liver cells. Increased 
peripheral utilization of glucose may be due to improved insulin binding to insulin 
receptors. Metformin administration also increases AMPK activity in skeletal muscle. 
AMPK is known to cause GLUT4 deployment to the plasma membrane, resulting in 
insulin-independent glucose uptake. The rare side effect, lactic acidosis, is thought to be 
caused by decreased liver uptake of serum lactate, one of the substrates of 
gluconeogenesis. In those with healthy renal function, the slight excess is simply cleared. 
However, those with severe renal impairment may accumulate clinically significant 
serum lactic acid levels. Other conditions that may precipitate lactic acidosis include 
severe hepatic disease and acute/decompensated heart failure. 
Pharmacodynamics: 
          Metformin is an oral antihyperglycemic agent that improves glucose tolerance in 
patients with NIDDM, lowering both basal and postprandial plasma glucose. Metformin 
is not chemically or pharmacologically related to any other class of oral 
antihyperglycemic agents. Unlike sulfonylureas, metformin does not produce 
hypoglycemia in either patients with NIDDM or healthy subjects and does not cause 
hyperinsulinemia. Metformin does not affect insulin secretion. 
Pharmacokinetics:  
Absorption: Absorbed over 6 hours, bioavailability is 50 to 60% under fasting 
conditions. Administration with food decreases and delays absorption. Some evidence 
indicates that the level of absorption is not dose-related, suggesting that absorption occurs 
through a saturable process. Limited data from animal and human cell cultures indicate 
that absorption occurs through a passive, non-saturable process, possibly involving a 
paracellular route. Peak action occurs 3 hours after oral administration. 
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Distribution: The volume of distribution is 63-276 liters/kilogram, likely due to less 
binding in the GI tract and/or different methods used to determine volume of distribution. 
Metabolism: Metformin is not metabolized.  
Elimination: Intravenous single-dose studies in normal subjects demonstrate that 
metformin is excreted unchanged in the urine and does not undergo hepatic metabolism 
(no metabolites have been identified in humans) nor biliary excretion. Approximately 
90% of the drug is eliminated in 24 hours in those with healthy renal function. Renal 
clearance of metformin is approximately 3.5 times that of creatinine clearance, indicating 
the tubular secretion is the primary mode of metformin elimination. 
Contraindications: Avoid alcohol. Take with food to reduce gastric irritation. 
Dosage: 500 or 750 mg per day 
 
4.3 Poly Ethylene Oxide (PEO-303) 
Synonyms: POLYOX. 
Chemical Structure:  (-O-CH2-CH2-)
 n OH. They have same chemical structure as PEG 
but higher molecular weights. n = average number of oxyethylene groups                                                 
Category:  Binding agent, Emollient, Cross linking agent, Film forming excipient. 
Description: Polyethylene oxide is a biocompatible polymer, which is marketed as 
“POLYOX”. It is a non-ionic, water soluble resin, with good lubricating, binding and film 
forming properties. POLYOX retards the release rate of drug/s and hence are widely used 
in pharmaceutical formulations like controlled release dosage forms, hot-melt technology 
and mucoadhesive dosage forms. 
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Solubility:  POLYOX water-soluble resins are readily soluble in and will thicken wide 
variety of organic solvents at various temperatures. Organic solvents include most haloge-
nated hydrocarbons, various ketones, alcohols, aromatic hydrocarbons and esters. 
POLYOX water-soluble resins are not generally soluble in aliphatic hydrocarbon 
solvents, glycols, diols and aliphatic ethers. 
Stability: The chemical stability of PEO was found to be dependent on both the storage 
and processing temperature, and the molecular weight of the polymer. Storage of the 
polymer above its melting point significantly increased polymer degradation, and the 
degradation process was accelerated as the molecular weight was reduced. Vitamin E, 
Vitamin E Succinate and Vitamin E TPGS were found to be suitable stabilizers for PEO; 
however, ascorbic acid was shown to degrade the polymer in solution.  
Applications: 
  Wide range of molecular weights offers formulation flexibility. 
 Versatile application in direct compression and granulation. 
 Rapid hydration and swelling for use in osmotic pump technologies. 
 Fast hydration and gel formation for use in hydrophilic matrices. 
 Meets requirements of the United States Pharmacopoeia (USP) and compliance with 
US Food Chemicals Codex (Moroni A., Ghebresellassie I., 1995). 
 
4.4 Carbopol 971P 
Synonyms: Acrylic acid,  2-propenoic acid,  Acroleic acid, Propenoic acid, Carbomer, 
Poly(acrylic acid).  
Chemical Name: Prop-2-enoic acid 
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Molecular Formula: C3H4O2 
Molecular Weight: 72.06266 g/mol. 
Category:  Binding agent, Film forming excipient. 
Description:  Carbopol polymers are polymers of acrylic acid cross-linked with 
polyalkenyl ethers or divinyl glycol. They are produced from primary polymer particles 
of about 0.2 to 6 micron average diameter. The flocculated agglomerates cannot be 
broken down into the ultimate particle when produced. Each primary particle can be 
viewed as a network structure of polymer chains interconnected by cross-links. Without 
the cross-links, the primary particle would be a collection of linear polymer chains 
intertwined but not chemically bonded. They swell in water up to 1000 times their 
original volume (and 10 times their original diameter) to form a gel when exposed to a pH 
environment above 4.0 to 6.0. Because the pKa of these polymers is 6.0 to 0.5, the 
carboxylate groups on the polymer backbone ionize, resulting in repulsion between the 
negative charges, which adds to the swelling of the polymer. 
Glass transition temperature: The glass transition temperature of Carbopol polymers is 
105°C (221°F) in powder form. However, the glass transition temperature decreases 
significantly as the polymer comes into contact with water. 
Applications: 
 Controlled release in tablets. Carbopol polymers offer consistent performance over a 
wide range of desired parameters (from pH-derived semi-enteric release to near 
zero-order drug dissolution kinetics) at lower concentrations than competitive 
systems. 
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 Bioadhesion in buccal, ophthalmic, intestinal, nasal, vaginal, and rectal applications. 
Noveon AA-1 USP polycarbophil is the recognized industry standard for 
bioadhesion. 
 Thickening at very low concentrations (less than 1%) to produce a wide range of 
viscosities and flow properties in topical lotions, creams and gels, oral suspensions, 
and in transdermal gel reservoirs. 
 Permanent suspensions of insoluble ingredients in oral suspensions and topicals. 
 Emulsifying topical oil-in-water systems permanently, even at elevated 
temperatures, with essentially no need for irritating surfactants (Perez-Marcos B et 
al., 1991). 
4.5   Microcrystalline Cellulose 
Synonyms: Avicel PH; Celex; cellulose gel; Celphere; Ceolus KG; crystalline cellulose; 
E460; Emcocel; Ethispheres; Fibrocel; Pharmacel; Tabulose; Vivapur. 
Chemical name: Cellulose 
Structure: 
                                  
 
 
 
Figure 5: Structure of Microcrystalline Cellulose 
Functional category: Adsorbent; suspending agent; tablet and capsule diluent; tablet 
disintegrant. 
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Description: Microcrystalline cellulose is a purified, partially depolymerized cellulose 
that occurs as a white, odourless, tasteless, crystalline powder composed of porous 
particles. 
Applications: Microcrystalline cellulose is widely used in pharmaceuticals, primarily as 
a binder/diluent in oral tablet and capsule formulations where it is used in both wet-
granulation and direct-compression processes. In addition to its use as a binder/diluent, 
microcrystalline cellulose also has some lubricant and disintegrant properties. 
Stability and Storage Conditions: Microcrystalline cellulose is a stable though 
hygroscopic material. The bulk material should be stored in a well-closed container in a 
cool, dry place. 
4.6 Spray Dried Lactose 
Synonyms: FlowLac 100; Lactopress Spray-Dried; NF Lactose–316 Fast Flo; NF 
Lactose–315; Pharmatose DCL 11; Pharmatose DCL 14; Super-Tab Spray-Dried. 
Chemical Name: Spray-dried lactose is a mixture of amorphous lactose, which is a 1:1 
mixture of a-and-b-lactose, and O-b-D-galactopyranosyl-(1→4)-a-D-glucopyranose 
monohydrate. 
Chemical Structure:  
                                            
 
Figure 6: Structure of Spray Dried Lactose 
Functional Category: Binding agent; directly compressible tablet excipient; tablet and 
capsule diluent; tablet and capsule filler. 
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Applications: Spray-dried lactose is widely used as a binder, filler-binder, and flow aid 
in direct compression tableting. 
Description: Lactose occurs as white to off-white crystalline particles or powder. It is 
odourless and slightly sweet-tasting.  
Storage: Spray-dried lactose should be stored in a well-closed container in a cool, dry 
place.                    
4.7 Cros Povidone 
Synonyms: E1201; Kollidon; Plasdone; poly[1-(2-oxo-1-pyrrolidinyl)ethylene]; 
polyvidone; polyvinylpyrrolidone; PVP; 1-vinyl-2-pyrrolidinone polymer. 
Chemical Name: 1-Ethenyl-2-pyrrolidinone homopolymer 
Chemical Structure:  
                                                 
 
Figure 7: Structure of Cros Povidone 
Molecular Formula: (C6H9NO)n 
Molecular Weight: 2.500 - 2.5000.000 g/mol. 
Category:  Disintegrant; dissolution aid; suspending agent; tablet binder. 
Description: Povidone occurs as a fine, white to creamy-white colored, odourless or 
almost odourless, hygroscopic powder. 
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Solubility: Freely soluble in acids, chloroform, ethanol (95%), ketones, methanol, and 
water; practically insoluble in ether, hydrocarbons, and mineral oil. 
Melting Point: Softens at 150 ̊C. 
Stability: Povidone darkens to some extent on heating at 150 ̊C, with a reduction in 
aqueous solubility. It is stable to a short cycle of heat exposure around 110–130 ̊C. 
Storage: Povidone may be stored under ordinary conditions without undergoing 
decomposition or degradation. However, since the powder is hygroscopic, it should be 
stored in an airtight container in a cool, dry place.      
                                                                                 
4.8 Aerosil 
Synonyms: Fumed silica, silicon dioxide, cristobalite. 
Chemical Name: dioxosilane 
Chemical Structure: 
                                                     
         Figure 8: Structure of Aerosil 
Molecular Formula: 60.0843 g/mol. 
Molecular Weight: SiO2 
Category: It serves as a universal thickening agent, in milkshakes for example, and 
an anticaking agent (free-flow agent) in powders.  
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Description:  Fumed silica is made from flame pyrolysis of silicon tetrachloride or 
from quartz sand vaporized in a 3000°C electric arc. Like silica gel, it serves as 
a desiccant. It is used in cosmetics for its light-diffusing properties. It is used as a 
light abrasive, in products like toothpaste. Other uses include filler in silicone elastomer 
and viscosity adjustment in paints, coatings, printing inks, adhesives and unsaturated 
polyester resins. Also used in the production of Kitty Litter. 
Melting Point: Stable up to 1610oC (2930oF) 
Solubility: Fumed silica will form dispersions in water, glycerine, butyl alcohol, mineral 
oil and a variety of other liquids, causing them to thicken or form gels. The dispersions 
often have thixotropic properties, i.e., viscosity that varies with rate of stirring.  
Stability/Storage: These products are stable indefinitely at room temperature if kept dry. 
Their tendency to adsorb moisture suggests an effective shelf life of about two years, 
once opened.                                         
                                                   4.9 Magnesium Stearate 
Synonyms: Magnesium octadecanoate; octadecanoic acid, magnesium salt; stearic acid, 
magnesium salt. 
Chemical Name: Octadecanoic acid magnesium salt. 
Category: Tablet and capsule lubricant. 
Description: Magnesium stearate is a very fine, light white, precipitated or milled, 
impalpable powder of low bulk density, having a faint odour of stearic acid and a 
characteristic taste. The powder is greasy to the touch and readily adheres to the skin. 
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Solubility: Practically insoluble in ethanol, ethanol (95%), ether and water; slightly 
soluble in warm benzene and warm ethanol (95%).                  
Stability & Storage: Magnesium stearate is stable and should be stored in a well closed 
container in a cool, dry place. 
4.10 Talc 
Synonyms: Altalc; E553b; hydrous magnesium calcium silicate; hydrous magnesium 
silicate; Luzenac Pharma; magnesium hydrogen metasilicate; Magsil Osmanthus; Magsil 
Star; powdered talc; purified French chalk; Purtalc; soapstone; steatite; Superiore. 
Chemical Name:  Talc 
Category:  Anticaking agent; glidant; tablet and capsule diluent; tablet and capsule 
lubricant. 
Description:  Talc is a very fine, white to grayish-white, odourless, impalpable, 
unctuous, crystalline powder. It adheres readily to the skin and is soft to the touch and 
free from grittiness. 
Solubility: Practically insoluble in dilute acids and alkalis, organic solvents, and water. 
Stability:  Talc is a stable material and may be sterilized by heating at 160 ̊c for not less 
than 1 hour. It may also be sterilized by exposure to ethylene oxide or gamma irradiation. 
Storage: Talc should be stored in a well-closed container in a cool, dry place. 
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5. MATERIALS AND METHODS 
5.1. Materials Used: Table 1: Materials used in Formulations 
S.No Ingredients Supplier 
1 Pioglitazone HCl Darwin pvt ltd. Vijayawada. 
2 Metformin HCl Darwin pvt ltd. Vijayawada. 
3 Polyethyleneoxide (PEO-303) Colorcon Asia pvt. Ltd 
4 Carbopol 971P 
HiMedia Pharmaceuticals Pvt 
Ltd, Mumbai 
5 Microcrystalline Cellulose SD Fine chemicals, Mumbai 
6 Spray Dried Lactose SD Fine chemicals, Mumbai 
7 Crospovidone SD Fine chemicals, Mumbai 
8 Aerosil SD Fine chemicals, Mumbai 
9 Magnesium Stearate SD Fine chemicals 
10 Talc SD Fine chemicals 
 
    5.2 Instruments Used: Table 2: Instruments used in Formulations 
S.NO Name of the Instrument Model And Manufacturer 
1 Digital balance 
 
Essae –teraoku Ltd 
2 Tablet dissolution test 
apparatus,USP 
 
Labindia, Disso 2000 
3 UV-Visible 
spectrophotometer 
 
Elico Ltd., SL 150, Hyderabad 
4 Compression machine 
 
Cadmach  Machinery , Kolkata 
5 Roche Friabilator 
 
Campbell Electronics 
 
6 
Monsanto Hardness Tester 
 
Shreeji Chemicals , Mumbai 
7 Disintegration apparatus Thermonic  Campbell electronics, Mumbai 
8 pH meter 
 
Elico Li 120 
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5.3. Methodology: 
UV Spectrophotometric method was used in the present study for the estimation 
of Pioglitazone HCl.  
 
 5.4. Confirmation of Pioglitazone HCl through UV spectral analysis: 
The λmax
 
of Pioglitazone HCl was observed by scanning the standard drug 
solution. Accurately weighed amount of Pioglitazone HCl (25mg) was dissolved in 
methanol to form a clear solution and it was made up to volume in 25ml volumetric flask 
with methanol.     1 ml of this solution was transferred in to 100 ml of volumetric flask 
and it was made up to volume with pH 1.2 buffer. The resulting solution (10 µg/ml of 
Pioglitazone HCl) was scanned over the range 200-400 nm against pH 1.2 buffer as blank 
using UV spectrophotometer. The wavelength at which maximum absorbance detected 
was recorded as the λmax. The absorption spectrum was noted at 269nm. 
 5.5 Construction of Calibration Curve: 
 Preparation of pH 1.2 (0.1N HCl) Buffer: The 8.5ml of hydrochloric acid (0.1N) 
is added 1000ml of distilled water. 
 Preparation of Stock solution: 25mg of Pioglitazone HCl was dissolved in 
methanol in 25ml volumetric flask to form a clear solution and later it was made 
up to volume with methanol. 
 Preparation of Required concentrations: 1ml of stock solution was withdrawn 
and made up to volume with pH 1.2 buffer in 10ml volumetric flask to obtain 
100µg/ml concentration. 0.5ml, 1.0ml, 1.5ml, 2.0ml, and 2.5ml of solution were 
withdrawn from the 100µg/ml concentration and made up to volume with pH 1.2 
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buffer in 10ml volumetric flak to obtain 5µg/ml, 10µg/ml, 15µg/ml, 20µg/ml and 
25µg/ml respectively, then analyzed Spectrophotometrically at 269nm 
5.6. Methods of Estimation of Metformin HCl: 
UV Spectrophotometric method was used in the present study for the estimation 
of Metformin HCl.  
 5.7. Confirmation of Metformin HCl through UV spectral analysis: 
The λmax
 
of Metformin HCl was observed by scanning the standard drug 
solution. Accurately weighed amount of Metformin HCl (25mg) was dissolved in distilled 
water to form a clear solution and it was made up to volume in 25ml volumetric flask 
with distilled water.1 ml of this solution was transferred in to 100 ml of volumetric flask 
and it was made up to volume with pH 1.2 buffer, PH 6.8 phosphate buffer and Distilled 
water. The resulting solution (10 µg/ml of Metformin HCl) was scanned over the range 
200-400 nm against pH 1.2 buffer and pH 6.8 phosphate buffer and Distilled water as 
blank using UV spectrophotometer. The wavelength at which maximum absorbance 
detected was recorded as the λmax. The absorption spectrum was noted at 232nm. 
 5.8 Construction of  Calibration Curve: 
 Preparation of pH 1.2 (0.1N Hal) Buffer: About 8.5ml of hydrochloric acid 
(0.1N) is added 1000ml of distilled water. 
 Preparation of pH 6.8 Phosphate Buffer: About 6.8 grams of Potassium 
dehydrogenate phosphate and suitable amount of Sodium hydroxide were 
dissolved in water until a clear solution was formed. Later it was made up to 
volume with water in 1000ml volumetric flask. 
 Preparation of Stock solution: 25mg of Metformin HCl was dissolved separately 
in Distilled water, pH 1.2 buffer and pH 6.8 phosphate buffer in 25ml volumetric 
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flask to form a clear solution and later it was made up to volume with respective 
buffers. 
 Preparation of Required concentrations: 1ml of stock solution was withdrawn 
and made up to volume with respective buffers in 10ml volumetric flask to obtain 
100µg/ml concentration. 0.2ml, 0.4ml, 0.6ml, 0.8ml, and 1ml of solution were 
withdrawn from the 100µg/ml concentration and made up to volume with 
respective buffers in 10ml volumetric flak to obtain 2µg/ml, 4µg/ml, 6µg/ml, 
8µg/ml and 10µg/ml respectively, then analyzed Spectrophotometrically at 
232nm.  
5.9 Calculation of the Theoretical Release Profile of Metformin from Bilayer 
Tablets: 
The total dose of Metformin for a once-daily SR formulation was calculated by 
the following equation. 
                                                 Dt = Dose (1+ (0.693×t)/ t1/2) 
                              Where, 
                                                Dt = total dose of drug, 
                                                Dose = dose of the IR part, 
                                                t = time (hr) during which the SR is desired (12 hr), 
                                                t1/2 = half-life of the drug (3 hr). 
                                                Dt = 132.5 (1+ (0.693×12)/ 3) = 500 
Hence, the formulation should release 132.5 mg in first hour like conventional 
tablets and 33.4 mg per hour up to 12 hours thereafter. 
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5.10 Preparation of Bilayer Tablets: 
In this present investigation Bilayered tablets of Pioglitazone HCl and Metformin 
HCl were formulated by Direct Compression Technique and Wet Granulation Technique. 
 5.10.1 Formulation of Immediate Release layer 
            Immediate release layer of Pioglitazone HCl was prepared by dry granulation 
technique. Pioglitazone, cross Povidone and Micro crystalline cellulose (MCC) were 
passed through sieve no # 40. The Sunset yellow lake was passed through sieve no #200. 
All the above were mixed in geometric proportion in a poly bag for 15 minutes. Aerosil 
and magnesium stearate were passed through sieve no # 60. Sifting was performed and 
the lubricated material was passed through the poly bag and mixed for 2 minutes. 
Compositions of different trial formulations for the IR layer were given in table 6.5.1. 
The final weight of the IR layer was fixed to 150 mg.  
 5.10.2 Formulation of Sustained Release layer 
 5.10.2. 1 Direct Compression Technique: 
             Sustained release layer of Metformin HCl was prepared by dry granulation 
technique. Metformin HCl, Poly ethylene oxide (PEO-303) and MCC were passed 
through sieve no # 40. All the above were mixed in geometric proportion in a poly bag for 
15 minutes. Talc and magnesium stearate were passed through sieve no # 60. Sifting was 
performed and the lubricated material was passed through the poly bag and mixed for 2 
minutes. Compositions of different trial formulations for the IR layer were given in table 
6.5.2. The final weight of the SR layer was fixed to 800 mg.  
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5.10.2. 2 Wet Granulation Technique: 
             Granules of Sustained release layer was formulated by uniformly mixing required 
amount of Metformin HCl with measured quantities of polymer and diluent as specified 
in the formulation table 6.5.3 using 1:1 ratio of ethanol and water as diluting fluid. Now 
the wet damp mass was passed through sieve no #20 and the granules were dried in hot 
air oven at 50oC. Talc and magnesium stearate were added and mixed thoroughly before 
compression of granules. The final weight of the SR layer was fixed to 800 mg.  
5.10.3 Compression of Bilayer Tablets: 
The extended release blend of Metformin HCl (800 mg) was compressed lightly 
using single punch tablet machine (Cad mach machinery Co Pvt.Ltd, India) equipped 
with 12mm circular, flat and plain punches. Over this compressed layer, the immediate 
release layer of Pioglitazone HCl (150mg) was placed and compressed to obtain hardness 
in the range of 6-7kg/cm2 to form a bilayered matrix tablet. 
 
5.11 Preformulation Studies: 
5.11.1 Bulk Density: 
           The powder blend of all formulations was evaluated separately inorder to 
determine their bulk densities. Powder blend was weighed (M) and later the weighed 
powder blend was transferred in to the measuring cylinder and volume occupied was 
noted (Vb ).  
                                      
Db =  Mass of the powder blend (M) 
                                                         Vol. occupied by powder blend (Vb )  
               Vb is known as the Bulk volume and Bulk density is expressed in terms of g/ml. 
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5.11.2 Tapped Density:  
             Powder blend was transferred into the measuring cylinder and subjected for 100 
tappings. The obtained volume was noted as the tapped volume. Tapped density is 
expressed as g/ml and tapped density is given by the formula; 
 
Dt =   Mass of the powder blend (M) 
               Tapped volume (Vt)     . 
5.11.3 Angle of Repose: 
               Angle of repose is the maximum angle possible between the surface of the pile 
of granules and the horizontal plane. This is one of the measures for flow properties. 
Powder blend was allowed to flow through the funnel attached to a stand and later height 
and radius of the heap of the powder blend formed was noted. Based on the height and 
radius obtained Angle of repose was calculated using the formula; 
                                       tan (θ) =  Height of the heap (h) 
                                                       Radius of the heap(r) 
Table 3: Specifications of Angle of Repose: 
Angle of repose Flow property 
<25 Excellent 
25-30 Good 
30-40 Passable 
>40 Poor 
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5.11.4 Carr’s Index (or) %Compressibility: 
             Carr’s Index is one more measure to know the flow properties. It is indicated by 
the letter (I) and expressed in terms of percentage 
 
                                       I =  Tapped density - bulk density × 100 
                                                       Tapped density 
            Table 4: Specifications of   %Compressibility: 
 
 
 
 
 
 
 
 
 
 
 
 
5.11.5 Hausner’s Ratio: 
The Hausner ratio is a number that is correlated to the flowability of 
a powder or granular material. 
 Hausner’s ratio was calculated by using the formula; 
Compressibility index (%) Flow properties 
<10 Excellent 
11-15 Good 
16-20 Fair 
21-25 Passable 
26-31 Poor 
32-37 Very poor 
>38 Very very poor 
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Hausner’s ratio =  Tapped density 
                                                                       Bulk density  
                  Table 5:  Specifications of   Hausners ratio: 
Hausners Ratio Type of flow 
Less than 1.25 Good  Flow 
1.25 – 1.5 Moderate 
Greater than.5 Poor flow 
 
5.12 Post Compressional Parameters: 
5.12.1. Weight Variation: 
Twenty   tablets were weighed collectively and individually. Average weight was 
calculated and based on the obtained weights % weight variation was calculated using the 
formula, 
% Weight Variation = Average weight – Individual weight × 100 
                                                           Average weight  
        Table 6: Specifications of   Weight Variation: 
Average weight of tablet % deviation 
80 mg or less 10 
More than 60mg but less than 250 mg 7.5 
250 mg or more 5 
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5.12.2. Hardness: 
Hardness of the tablet was tested by placing the tablet longitudinally in between 
the two plungers of the Monsanto tablet hardness tester and the obtained hardness was 
mentioned in terms of kg/sq.cm. 
Limits for Hardness are 4-6kg/sq.cm. 
5.12.3. Friability: 
The friability of the tablets was determined by Roche Friabilator in which the 
tablets were subjected to the combined effect of abrasions and shock in a plastic chamber 
revolving at 25rpm and dropping the tablets at a height of 6 inches in each revolution. 
Pre weighed sample of tablets were placed in the friabilator and allowed to rotate 
for 100 revolutions. Later the tablets were dedusted and the tablets were reweighed. 
Percent friability is given by the formula;                            
                                                  %F = (1-W/W0) ×100 
                             Where, W0 is the weight of the tablets before the test 
                                           W is the weight of the tablets after the test  
Limits for friability are %friability should not be more than 1%. 
5.13 Estimation of Drug Content: 
Equivalent to 10mg each of Pioglitazone HCl and Metformin HCl was accurately 
weighed from powdered bilayered tablets and it was dissolved in methanol and distilled 
water respectively to form a clear solution. Later it was made up to volume with methanol 
and distilled water respectively. One ml of the sample was withdrawn, suitably diluted 
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with pH 1.2 buffer and pH 6.8 phosphate buffer respectively and analysed 
spectrophotometrically at 269nm and 232nm respectively. 
5.14 In vitro Dissolution Studies: 
  An  in vitro drug release study from the prepared bilayered tablets, in triplicate , 
was determined using the USP eight station Dissolution Rate Test Apparatus(model QAE 
016 and NRE 002, M/S Campbell Electronics) employing a paddle stirrer . With 900 ml 
of pH of 1.2 and followed by phosphate buffer pH 6.8 was used as dissolution media and 
maintained at 37±0.5oC at a rotational speed of 100 rpm, for 2 hrs and 10 hrs respectively. 
Then the dissolution samples were analysed in UV-VIS double beam spectrophotometer, 
while keeping the dissolution media as a blank at 232nm. 
5.15 Drug Release Kinetics: 
To study the mechanism of drug release from the SR layer of the matrix tablets, 
the dissolution data were fitted into the following equations: 
5.15.1 Zero order equation: 
                               
                                    Qt = Q0 + k0t                                            -------------------- (1) 
 
Where, Qt is the amount of drug released at time t, Q0 is the initial amount of drug 
in the solution (more times, Q0 =0) and k0 is the zero-order release rate (Kenneth A. 
Connors, 1991). 
5.15.2 First order equation: 
                                 ln Qt = ln Q0 = k1t                                      -------------------- (2) 
Where, Qt is the amount of drug released at time t, Q0 is the initial amount of drug 
in the solution and k1 is the first-order release rate constant (Kenneth A. Connors, 1991). 
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5.15.3 Higuchi’s equation: 
                                 Q = kH t1/2                                                    -------------------- (3) 
 
Where, Q is the amount of drug released at time t, kH is the Higuchi diffusion rate 
constant (Higuchi W I, 1962). 
5.15.4 Koresmeyer’s equation: 
                                 Mt / M∞ = Ktn                                             -------------------- (4) 
Where, Mt is the amount of drug released at time t, M∞ is the amount of drug 
released after infinite time, k is a kinetic constant incorporating structural and geometric 
characteristics of the tablet, and n is the diffusional exponent of the drug release 
mechanism (Koresmeyer et al., 1977). 
5.16 Similarity factor: 
  The similarity factor (f2) is used to compare the dissolution profile of each 
formulation with that of marketed formulation. In this approach, recommended by the 
FDA guidance for the industry, a value between 50 and 100, the two profiles are nearly 
identical (Shah V.P et al 1998). 
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6. Results and Discussion 
6.1 Estimation of Pioglitazone HCl: 
  
Table 7: Calibration Curve Data 
S.No. Concentration(µg/mL) Absorbance 
1 5 0.093±0.001 
2 10 0.192±0.003 
3 15 0.291±0.004 
4 20 0.373±0.003 
5 25 0.449±0.002 
 
       
                     
Figure 9:   Calibration Curve for Pioglitazone HCl 
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6.2 Estimation of Metformin HCl: 
 
Table 8 :Calibration Curve Data  
(In pH 1.2 buffer) 
S.No. Concentration(µg/mL) Absorbance 
1 2 0.025±0.003 
2 4 0.042±0.002 
3 6 0.060±0.003 
4 8 0.074±0.001 
5 10 0.089±0.002 
    
 
 
Figure 10:   Calibration Curve for Metformin HCl 
(In pH 1.2 buffer) 
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Table 9: Calibration Curve Data  
(In pH 6.8 phosphate buffer) 
S.No. Concentration(µg/mL) Absorbance 
1 2 0.156±0.001 
2 4 0.292±0.001 
3 6 0.442±0.002 
4 8 0.585±0.001 
5 10 0.728±0.003 
    
 
  
 
Figure 11:   Calibration Curve for Metformin HCl 
(In pH 6.8 phosphate buffer) 
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Table 10 : Calibration Curve Data  
(In Distilled water) 
S.No. Concentration(µg/mL) Absorbance 
1 2 0.142±0.002 
2 4 0.283±0.002 
3 6 0.422±0.001 
4 8 0.560±0.003 
5 10 0.684±0.002 
    
 
 
 Figure 12:   Calibration Curve for Metformin HCl  
(In Distilled water) 
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6.3 Preformulation Studies for IR layer: 
             Preformulation studies were carried out through Drug-Excepient compatibility 
studies using FTIR.  
 
 
 
Figure 13: FT-IR Spectrum of pure Pioglitazone HCl 
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Figure 14: FT-IR Spectrum of pure Crospovidone 
 
 
Figure 15: FT-IR Spectrum of prepared formulation 
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Figure 16: FT-IR Spectrum of pure Metformin HCl 
 
 
Figure 17: FT-IR Spectrum of pure PEO-303 
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Figure 18:FT-IR Spectrum of pure CARBOPOL 971P 
 
Figure 19: FT-IR Spectrum of formulation prepared with PEO-303 
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Figure 20: FT-IR Spectrum of formulation prepared with CARBOPOL 971P 
 
6.4 Micromeretic properties: 
Table 11: Micromeretic parameters for IR layer formulations 
Formulation 
code 
Micromeretic properties  
Bulk 
density 
(gm/ml) 
Tapped 
density 
(gm/ml) 
Angle of 
repose 
(o) 
Compressibility 
index 
 (%) 
Hausner’s 
ratio 
F1 0.598 0.643 21.5 16.36 1.16 
F2 0.659 0.732 21 15.97 1.23 
F3 0.688 0.768 22.5 16.08 1.19 
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Table 12: Micromeretic Parameters for SR layer Formulated with 
 PEO-303 
Formulatio
n code 
Micromeretic properties 
Bulk 
density 
 ( gm/ml) 
Tapped 
density 
(gm/ml) 
Angle of 
repose 
(o) 
Compressibility 
index 
(%) 
Hausner’s 
ratio 
F4 0.576 0.654 21.5 16.07 1.18 
F5 0.532 0.612 23 15.90 1.17 
F6 0.569 0.636 21 15.50 1.19 
F7 0.592 0.664 22.5 16.67 1.21 
F8 0.657 0.743 22 16.07 1.16 
F9 0.689 0.776 24 17.63 1.14 
 
Table 13: Micromeretic Parameters for SR layer Formulated with      
CARBOPOL 971P 
Formulatio
n code 
Micromeretic properties  
Bulk 
density 
 (gm/ml) 
Tapped 
density 
(gm/ml) 
Angle of 
repose  
(o) 
Compressibility 
index  
(%) 
Hausner’s 
ratio 
F10 0.546 0.624 22.5 16.09 1.19 
F11 0.572 0.642 22 16.76 1.16 
F12 0.587 0.676 21.5 16.50 1.21 
F13 0.643 0.714 21 15.97 1.18 
F14 0.623 0.703 21.5 16.50 1.17 
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6.5 Formulation tables: 
 
Table 14: Composition for IR layer of Bilayered tablet 
S.No Ingredients (mg/tab) 
Formulations  
F1 F2 F3 
1 Pioglitazone HCl 15 15 15 
2 Cross povidone 2.5 5 7.5 
3 Lactose 74.5 72 69.5 
4 MCC 50 50 50 
5 Aerosil 3 3 3 
6 Mg stearate 3 3 3 
7 Sunset yellow 2 2 2 
Total Weight 150 150 150 
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Table 15: Composition for SR layer of Bilayered Tablets prepared by Direct 
Compression technique 
S.No. Ingredients (mg/tab) 
Formulations 
F4 F5 F6 F7 F8 F9 
1 Metformin HCl 500 500 500 500 500 500 
2 PEO-303 50 100 150 200 250 296 
3 MCC 246 196 146 96 46 - 
4 Mg stearate 2 2 2 2 2 2 
5 Talc 2 2 2 2 2 2 
Total Weight 800 800 800 800 800 800 
 
 
Table 16: Composition for SR layer of Bilayered Tablets prepared by Wet 
Granulation technique 
S.No. Ingredients (mg/tab) 
Formulations 
F10 F11 F12 F13 F14 
1 Metformin HCl 500 500 500 500 500 
3 Carbopol 971P 50 75 100 150 200 
4 MCC 246 221 196 146 96 
5 Mg stearate 2 2 2 2 2 
6 Talc 2 2 2 2 2 
7 
Diluting Fluid    
(ethanol and water 1:1) qs qs qs qs qs 
Total Weight 800 800 800 800 800 
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6.6 Post Compressional Parameters: 
 
Table 17: Post Compressional Parameters Bilayered Tablets of Pioglitazone HCl 
and Metformin HCl by Direct Compression technique 
Formulatio
n code 
Average 
Weight 
(±SD) 
Thick 
ness 
(mm) 
Hard 
ness 
kg/cm2 
Friabilit
y (%) 
Drug Content (%) 
Pioglitazon
e HCl 
 
Metformin 
HCl 
F4 950.4±0.55 8.47±0.01 7.30±0.04 
0.23±0.0
5 98.75±0.73 99.40±0.77 
F5 948.6±1.34 8.48±0.03 7.34±0.42 
0.21±0.0
6 98.26±1.08 98.89±1.73 
F6 947.6±0.89 8.52±0.03 7.21±0.23 0.2±0.05 98.50±1.05 
100.20±0.4
5 
F7 
 
948.8±0.8
4 
 
8.52±0.02 
 
7.11±0.17 
 
0.17±0.0
4 
 
97.09±0.73 
 
99.39±0.73 
F8 
 
950.4±0.5
2 
 
8.51±0.02 
 
7.17±0.30 
 
0.19±0.0
3 
 
99.03±0.89 
 
99.62±0.86 
F9 
 
949.6±0.4
8 
 
8.50±0.03 
 
7.28±0.24 
 
0.20±0.0
8 
 
99.24±0.56 
 
99.64±0.52 
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Table 18: Post Compressional Parameters of Pioglitazone HCl and Metformin HCl 
by Wet Granulation technique 
Formulatio
n code 
Average 
Weight 
(±SD) 
Thicknes
s (mm) 
Hardnes
s kg/cm2 
Friabilit
y (%) 
Drug content (%) 
Pioglitazon
e HCl 
 
Metformi
n HCl 
F10 950.4±0.3
5 
8.14±0.0
5 
7.28±0.1
1 
0.22±0.0
4 99.75±0.43 
99.10±0.3
7 
F11 949.6±0.9
8 
8.09±0.0
2 
7.30±0.4
1 
0.21±0.0
2 99.26±1.18 
99.37±1.0
3 
F12 950.6±0.4
6 
8.19±0.0
2 
7.21±0.4
3 
0.23±0.0
4 98.90±1.01 
99.28±0.7
5 
F13 951.8±0.7
8 
8.19±0.0
3 
 
7.19±0.1
5 
0.19±0.0
3 99.09±0.23 
99.09±0.3
3 
F14 950.6±0.4
1 
8.10±0.0
5 
7.14±0.2
0 
0.17±0.0
4 98.03±0.59 
98.72±0.4
6 
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6.7 Cumulative Percent Drug Release: 
Table 19:   Cumulative Percent Drug Release data for IR layer formulations: 
 
Time in 
minutes 
Cumulative % drug release 
F1 F2 F3 
0 0 0 0 
1 29.06±1.62 39.38±1.65 68.13±0.31 
2 37.50±0.31 51.15±1.10 74.06±0.36 
3 47.71±1.26 62.19±0.31 77.50±0.18 
4 53.96±0.95 71.77±0.48 82.19±0.36 
5 61.35±0.95 76.25±0.83 88.75±0.18 
6 64.79±0.79 80.63±0.54 91.56±0.18 
7 68.65±0.36 84.48±0.36 96.56±2.17 
8 72.50±1.08 89.06±0.31 97.19±1.98 
9 75.94±1.43 91.56±0.83 97.81±0.72 
10 78.65±0.79 92.40±0.36 99.69±0.18 
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Table 20:  Cumulative Percent Drug Release for Bilayered Tablets Formulated by 
Direct Compression technique 
Time 
(hrs) 
Cumulative %drug released 
F4 F5 F6 F7 F8 F9 
0 
          0 
 
0 0 0 0 0 
1  94.62±0.37 90.67±0.37 87.3±0.37 62.64±0.78 32.64±1.16 20.76±1.64 
2 95.04±0.00 93.43±0.19 90.57±0.10 80.94±0.10 46.26±0.94 31.64±1.39 
3 - - - 94.79±0.59 61.25±1.48 39.05±1.42 
4 - - - 96.11±0.16 67.38±1.86 47.5±1.06 
6 - - - - 76.31±1.80 54.17±0.97 
8 - - - - 84.3±1.92 60.31±1.29 
10 - - - - 91.3±1.32 69.47±1.02 
12 - - - - 99.06±0.09 79.62±0.11 
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Table 21:   Cumulative Percent Drug Release for Bilayered Tablets Formulated by 
Wet Granulation technique: 
 
Time in 
hrs 
Cumulative %drug released 
F10 F11 F12 F13 F14 
0 
0 
 
0 0 0 0 
1 
61.38±0.37 
 
48.84±0.63 
 
42.3±0.62 
 
36.6±0.58 
 
32.88±0.99 
 
2 
82.68±1.40 
 
63.9±0.65 59.7±0.37 50.1±0.68 44.1±1.00 
3 
- 78.56±0.75 81.69±0.61 67.53±0.35 61.29±1.36 
4 
- 83.04±0.93 85.60±0.86 70.14±1.00 64.38±1.73 
6 
- - 89.51±0.54 79.26±0.46 68.45±1.23 
8 - - - 
82.68±0.59 70.73±1.03 
10 - - - 
92.78±0.52 73.42±1.11 
12 - - - 
99.21±0.05 74.72±1.00 
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6.8 Cumulative Percent Drug Release Profiles: 
                                                                                                                                                              
 
Figure 21:   Cumulative Percent Drug Release profiles for IR layer formulations 
 
 
Figure 22:Cumulative Percent Drug Release profiles for Bilayered Tablets 
Formulated by Direct Compression technique 
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Figure 23: Comparision of Percent Drug Release profiles for F8 and Marketed 
formulation 
 
 
Figure 24: Cumulative Percent Drug Release profiles for Bilayered Tablets 
Formulated by Wet Granulation technique 
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Figure 25: Comparision of Percent Drug Release profiles for F13 and Marketed 
formulation 
 
6.9 Zero Order Release Plots: 
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Figure 26:    Zero Order Release Plots for Bilayered Tablets Formulated   by Direct 
Compression technique 
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Figure 27:    Zero Order Release Plots for Bilayered Tablets Formulated by 
Wet Granulation technique 
 
6.10 First Order Release Plots: 
 
                    
 
Figure 28:    First Order Release Plots for IR layer formulations 
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Figure 29:    First Order Release Plots for Bilayered Tablets Formulated by Direct 
Compression technique 
 
 
           
 
Figure 30:    First Order Release Plots for Bilayered Tablets Formulated by Wet 
Granulation technique 
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6.11 Higuchi’s   Plots: 
 
               
Figure 31: Higuchi’s Plots for Bilayered Tablets Formulated by Direct Compression 
technique 
 
 
               
 
Figure 32: Higuchi’s Plots for Bilayered Tablets Formulated by Wet Granulation 
technique 
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6.12 Peppas Plots: 
 
      
 
 
 
 
Figure 33:   Peppas Plots for Bilayered Tablets Formulated by Direct Compression 
technique 
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Figure 34:   Peppas Plots for Bilayered Tablets Formulated by Wet Granulation 
technique 
 
6.13 In-vitro Drug Release Kinetics: 
Table 22:   In-vitro Drug Release Kinetics for IR layer formulations: 
 
Formulation 
code 
Correlation 
coefficient 
K(hr-1) 
Zero order 
(mol.L-1.min-1) 
First order 
(min-1) 
F1 0.875 0.981 0.142 
F2 0.812 0.990 0.248 
F3 0.600 0.916 0.432 
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Table 23:   In-vitro Drug Release Kinetics for Bilayered Tablets Formulated by 
Direct Compression technique: 
 
Formulation 
Code 
Zero order First order Higuchi Peppas 
K  
Value 
 (mol.L-1.h-1) 
r
2
 
 
value 
K 
 value  
(h-1) 
r
2
  
 value 
K    
 value 
r
2 
value 
n   
value 
r
2 
 
value 
F4 28.03 0.311 0.888 0.321 0.245 0.159 0.001 0.159 
F5 31.27 0.405 1.179 0.567 13.40 0.546 0.075 0.665 
F6 35.86 0.592 1.440 0.915 32.13 0.961 0.176 0.983 
F7 4.90 0.464 0.227 0.646 16.12 0.743 0.199 0.896 
F8 7.10 0.855 0.237 0.990 27.36 0.979 0.466 0.990 
F9 5.69 0.911 0.115 0.917 22.92 0.983 0.589 0.991 
 
Table 24:  In-vitro Drug Release Kinetics for Bilayered Tablets Formulated by Wet 
Granulation technique: 
 
Formulation 
Code 
Zero order First order Higuchi Peppas 
K  
value 
(mol.L-1.h-1) 
r
2  
value 
K    
value            
(h-1)  
r
2
   
value 
K    
value 
r
2   
value 
n  
 value 
r
2  
value 
F10 37.35 0.896 0.829 0.991 57.25 0.997 0.482 0.998 
F11 18.57 0.859 0.430 0.979 40.20 0.988 0.454 0.994 
F12 14.07 0.820 0.393 0.948 37.95 0.952 0.469 0.983 
F13 7.010 0.830 0.313 0.891 26.71 0.968 0.430 0.985 
F14 5.251 0.716 0.108 0.836 20.09 0.892 0.408 0.952 
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6.14 Discussion: 
                          The present work was carried out on the Design and Development of 
Bilayered tablets of Pioglitazone HCl and Metformin HCl comprising of immediate 
release layer for sudden onset of action followed by Sustained release layer to maintain 
the steady state concentrations of the drug. Micro crystalline cellulose used as diluents 
and release retarding polymers Polyethylene oxides (PEO-303) and Carbopol 971P were 
used in this investigation. 
                         Calibration plots for Pioglitazone HCl and Metformin HCl shows good 
linearity indicating that selection of UV-spectrophotometry method for estimation of 
above named drugs is correct.  
6.14.1 Preformulation studies: 
Drug and Excepient compatibility studies of IR layer:  
        The individual IR spectra of Pioglitazone HCl, Crospovidone and of optimized 
formulation (F3) were shown in the figures 6.3.1, 6.3.2, and 6.3.3. The following 
principle peaks were observed from the IR spectral analysis.  
The following principle peaks were observed from IR spectra of Pioglitazone HCl: 
 N-H Stretching                              -             2967.14cm-1 
 C-H  Stretching                             -             2912.46cm-1 
 C-H  Stretching                             -                2735.98cm-1 
 C = O Stretching                           -             1739.95cm-1 
 C-O-Ar Stretching                        -             1242.94cm-1 
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                 The observed principle peaks were identical in the IR spectra of drug and in the 
IR spectra of the optimized formulation (F3). Hence there was no chemical or physical 
interaction between the drug and the excipient used in this investigation. 
 
Drug and Excepient compatibility studies of SR layer:  
        The individual IR spectra of Metformin HCl, PEO-303, Carbopol 971P and of 
optimized formulations (F8 and F13) were shown in the figures 6.3.4, 6.3.5, 6.3.6, 6.3.7 
and 6.3.8. The following principle peaks were observed from the IR spectral analysis.  
The following principle peaks were observed from IR spectra of Metformin HCl: 
 N-H (Primary amine) Stretching                              -             3366.19cm-1 
 N-H (Primary amine) Stretching                              -             3289.73cm-1 
 N-H (Secondary amine) Stretching                      -                3144.25cm-1 
 C -N Stretching                                                         -             1623.21cm-1 
 C -N Stretching                                                         -             1546.07cm-1 
 
The observed principle peaks were identical in the IR spectra of drug and in the IR 
spectra of the optimized formulation (F8 and F13). Hence there was no chemical or 
physical interaction between the drug and the excipients used in this investigation. 
6.14.2   Studies on Immediate release layer of Pioglitazone HCl: 
Precompressional parameters such as angle of repose, bulk density, tapped 
density, compressibility index, Hausner’s ratio for physical mixtures of immediate release 
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layer formulations (F1, F2 and F3) were evaluated and results were reported in Table – 
6.4.1. 
Bulk density and tapped density for the formulations were in the range of 0.589-
0.892gm/ml and 0.650-0.946 gm/ml. The angle of repose for the formulations was found 
to be in the range of 19.5o- 25o.  Compressibility index and Hauser’s ratio were in the 
range of 15.00-25.00% and 1.04-1.19. The results obtained confirm that all the 
formulations exhibited the good flow properties and good packing characteristic. 
Studies on In-vitro dissolution profile of Immediate release layer formulations: 
Based on the results, the cumulative % drug released for F1, F2 and F3 
formulations were found to be 78.65±0.71, 92.40±0.36, and 99.69±0.18 respectively. The 
formulations followed first order kinetics with a regression value of 0.981, 0.990, and 
0.916 respectively.  
The results depict that, the maximum amount of drug was released from the 
formulation F3 when compared to other formulations F1and F2. This is due to the more 
concentration of superdisintegrant in the formulation. Hence, formulation F3 was 
confirmed as an optimized immediate release layer.  
6.14.3 Studies on SR layer of Metformin HCl 
Studies on SR layer formulated by Direct Compression technique: 
The precompressional parameters ie; Bulk density and tapped density for the 
formulations were in the range of 0.589-0.892gm/ml and 0.650-0.946 gm/ml. The angle 
of repose for the formulations was found to be in the range of 19.5o- 25o.  Compressibility 
index and Hausner’s ratio were in the range of 15.00-25.00% and 1.04-1.19. Similarly the 
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post compressional parameters like, weight variation, hardness, friability, and percent 
drug content were found to be within the limits. 
All the formulations (F4 to F7) showed the sudden release of Metformin HCl in 
the initial hours, which is due to faster dissolution of the highly water soluble drug from 
the superficial layers of matrix and its diffusion out of the matrix which leads to the entry 
of dissolution media through the pores. F8 showed sustained drug release up to 12 hours 
which is nearly identical to the release profile of marketed formulation. F9 showed a 
release over 12 hours, due to increase in the concentration of PEO-303 in the formulation, 
resulted in a decreased drug release rate.  
     A sufficient polymer concentration in the hydrophilic matrix system is required to 
form a uniform gel barrier around the tablet upon hydration. This barrier is expected to 
prevent the drug from immediate release into the dissolution medium. If the polymer 
concentration is low, a complete gel layer may not form resulting in a significant amount 
of drug being released too quickly in the worst case, tablet disintegration. F4 to F7 failed 
to sustain the drug release due to in sufficient polymer concentration in the matrix system. 
It can be seen that polymer concentration of less than 30% are insufficient to produce 
adequate extended release of metformin HCl. Similar results were reported by Dow for 
HPMC  ER matrices. The in vitro dissolution study also shows that an increased PEO 
level in the formulation resulted in a decreased drug release rate (F9). 
A further increase in PEO concentration from 30% to 60% resulted in a slower 
drug release profile. This effect of slower Metformin HCl release for higher polymer level 
is due to the  longer period of time required to reach the polymer chain disentanglement 
concentration at the tablet surface, which in turn equates to greater resistance of the 
matrix to surface erosion. 
                                                                                                           Results and Discussion          
 
J.K.K.Nattraja College of Pharmacy 83 
 
To ascertain the mechanism of drug release, in-vitro release data were fitted into 
various release kinetic models such as First order, zero order, Higuchi, and Peppas. The 
first order plots obtained were linear when compared with the zero order plots. Hence the 
order of release for formulations followed first order kinetics. From the above results F8 
formulation was best among other formulations and the release was governed by Fickian 
diffusion.   
Studies on SR layer formulated by Wet Granulation technique: 
The Cumulative % drug release for F10, F11, F12, F13 and F14 was 82.68±1.40, 
83.04±0.93, 89.51±0.54, 99.21±0.05 and 74.72±1.00. All the formulations (F10 to F12) 
showed the sudden release of Metformin HCl in the initial hours, which is due to faster 
dissolution of the highly water soluble drug from the superficial layers of matrix and its 
diffusion out of the matrix which leads to the entry of dissolution media through the 
pores. F13 showed sustained drug release up to 12 hours which is nearly identical to the 
release profile of marketed formulation. F14 showed a release over 12 hours, due to 
increase in the concentration of Carbopol 971P in the formulation, resulted in a decreased 
drug release rate.  
A sufficient polymer concentration in the hydrophilic matrix system is required to 
form a uniform gel barrier around the tablet upon hydration. This barrier is expected to 
prevent the drug from immediate release into the dissolution medium. If the polymer 
concentration is low, a complete gel layer may not form resulting in a significant amount 
of drug being released too quickly in the worst case, tablet disintegration. F10 to F12 
failed to sustain the drug release due to insufficient polymer concentration in the matrix 
system. It can be seen that polymer concentration of less than 18% are insufficient to 
produce adequate extended release of Metformin HCl. The in vitro dissolution study also 
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shows that an increased Carbopol level in the formulation resulted in a decreased drug 
release rate (F14). 
A further increase in Carbopol concentration above 18% resulted in a slower drug 
release profile. This effect of slower Metformin HCl release for higher polymer level is 
due to the  longer period of time required to reach the polymer chain disentanglement 
concentration at the tablet surface, which in turn equates to greater resistance of the 
matrix to surface erosion. 
To ascertain the mechanism of drug release, in-vitro release data were fitted into 
various kinetic models such as First order, zero order, Higuchi, and Peppas. The first 
order plots obtained were linear when compared with the zero order plots. Hence the 
order of release for formulations followed first order kinetics. From the above results F13 
formulation was best among other formulations and the release was governed by Fickian 
diffusion.   
 The similarity factor (f2) was also calculated in order to compare optimized 
formulation (F8 and F13) with that of the reference formulations. Comparission of the 
profiles indicated that the formulations (F8and F13) had a profile similar to the reference 
formulation (f2 = 51.41and 51.21) respectively. So these two formulations were 
comparable with the marketed formulation. 
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7. SUMMARY AND CONCLUSION 
In the present investigation, Sustained release Bilayered tablets of Pioglitazone 
HCl and Metformin HCl were formulated by Direct Compression technique and Wet 
Granulation technique. Bilayered tablets comprise of IR for sudden onset of action 
formulated with Crospovidone and SR layer formulated with Polyethylene oxide (PEO-
303) and Carbopol 971 P inorder to sustain the drug release. 
Drug-excepient compatibility were studied by FT-IR spectral analysis, the results 
revealed that there were no interactions between drug and excepients in this investigation 
for the development of the Bilayered tablet formulation. 
The Precompressional parameters for IR, SR layer formulations ie; Angle of 
repose, Bulk density, Tapped density, Compressibility index, Hausner’s ratio were 
studied and found to be in satisfactory limits indicating that the Physical mixtures of the 
formulations are suitable to formulate the Bilayered tablets. Postcompressional 
parameters for Bilayered tablets ie; Weight variation, Hardness, Friability, Drug content, 
were evaluated and the results obtained were satisfactory. 
The in-vitro drug dissolution studies were carried out for the formulations in pH 
1.2 and pH 6.8 phosphate buffer for 2hrs and 10hrs respectively and based on the in-vitro 
drug release profile IR layer formulation (F3) was optimized for the further development 
of Bilayered tablets. The formulation F8 comprising of PEO-303 and the formulation F13 
comprising of CARBOPOL 971P sustained the drug release for a period of 12 hrs. 
Dissolution profile of formulations F8 and F13 were compared with the dissolution 
profile of marketed formulation and Similarity factor for the formulations F8 and F13 was 
found to be 51.41 and 51.21 respectively. 
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           The similarity factor (f2) was also calculated in order to compare optimized 
formulation (F8 and F13) with that of the reference formulations. Comparission of the 
profiles indicated that the formulations (F8and F13) had a profile similar to the reference 
formulation (f2 = 51.41and 51.21) respectively. So these two formulations were 
comparable with the marketed formulation. 
The conclusions drawn from the results include: 
 Pioglitazone HCl and Metformin HCL and the excepients selected for this 
investigation were compatible and it was confirmed by FT-IR studies.   
 Precompressional and Postcompressional parameters were found to be within the 
satisfactory limits and hence suitable to formulate Bilayered tablets.  
 The order of cumulative % drug release from IR layer formulations was found to 
be F3>F2>F1.  
 The IR layer formulation ie; F3 was optimized because it   released the maximum 
amount of the drug. 
 The results of in-vitro drug release profile of Bilayered tablets depicts that 
increase in polymer concentration, increases the retardation of drug release from 
the SR layer of a Bilayered tablet. 
 The desired drug release rate obtained for F8 and F13 was found to be near to that 
of the theoretical desired drug release rate. 
 The desired drug release rate obtained for F8 and F13 was found to be near to that 
of the drug release rate of Marketed formulation. 
 The formulations F8 and F13 were suitable to  sustain the drug release for a period 
of 12hrs, followed first order kinetics exhibited Higuchi’s model and Krosmeyer-
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Peppas exponential coefficient ‘n’ < 0.5 indicates that the release was governed by 
Fickian diffusion. 
 Hence can conclude that formulated Bilayered tablets of Pioglitazone HCl and 
Metformin HCl were developed successfully with IR layer comprising of 
Crospovidone and SR layer comprising of PEO-303 and CARBOPOL 971P as 
polymers by  Direct Compression technique and Wet Granulation technique.  
 From the above results it can be concluded that by using PEO-303 and 
CARBOPOL 971P we can successfully formulate Bilayer tablets of Pioglitazone 
HCl and Metformin HCl which showed sustained drug release up to 12hours. 
FUTURE WORK TO BE DONE 
Based on the above studies the sustained release bilayer matrix tablets of 
Pioglitazone HCl and Metformin HCl with polymers such as PEO-303 and CARBOPOL 
971P could be suitable for sustaining the drug release over a prolonged period. The 
formulations prepared were found to be linear in releasing the drug for a prolonged period 
of time i.e. 12 hours. Then these formulations can be further subjected to 
pharmacodynamic and pharmacokinetic studies in a suitable animal model. Hence the 
above found formulations may be suitable for once a day administration. 
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